American pharmaceutical company Moderna has released the results of an initial analysis of a clinical trial of the new coronavirus vaccine in children aged 12 to 17 years, with efficacy in at least one vaccinated person. Revealed that it was 96%.
The vaccine developed by Moderna has been approved for emergency use by the FDA (Food and Drug Administration) in the United States for people aged 18 and over, but more than 3,200 people aged 12 to 17 are aiming to expand the scope of vaccination. Clinical trials are being conducted on the subject.
Moderna announced on the 6th that initial analysis showed that it was 96% effective in people who received at least one vaccination.
Regarding safety, although pain, headache and fever have been reported at the time of inoculation, no serious health effects have been confirmed.
Moderna will continue to accumulate more data and discuss with regulators the growing age of vaccinations.
In addition, Moderna also published the results of a study in which additional vaccines were given to combat the mutant virus.
According to this, after two inoculations of the modelna vaccine, six months to eight months later, the same vaccine or a newly developed vaccine corresponding to the mutant virus was additionally inoculated. It means that the levels of antibodies against the first mutant virus found in South Africa and Brazil have increased.
Regarding this result, Moderna said, "I gained confidence in the strategy of obtaining a protective effect against the mutant virus by additional inoculation."